CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis

Table 1

Serum cytokine levels in MS cases.   

Analyte	MS (ng/mL)	Control (ng/mL)
IL-1α	6.6 ± 0.8	5.3 ± 2.2
IL1b	8.8 ± 0.9	6.6 ± 0.4
IL-1ra	23 ± 7.3	38 ± 17.2
IL-2Ra	320.3 ± 51.9	36.3 ± 4.1
	< 0.04
IL-2	56.23 ± 32	78 ± 27
IL-3	82.0 ± 12.9	67.2 ± 13.4
IL4	87.8 ± 15.4	63.0 ± 18.6
IL-5	24.12 ± 17	33 ± 23
IL-7	5.2 ± 0.3	6.2 ± 0.8
IL-8	4.7 ± 0.5	6.6 ± 1.6
IL-9	9.7 ± 1.7	7.3 ± 1.4
IL10	73.6 ± 6.2	68.5 ± 10.2
IL-12p40	4005.7 ± 327.1	86.0 ± 6.1
	< 0.00015
IL-12(p70)	90.2 ± 17.9	84.1 ± 8.6
IL-13	2.7 ± 0.3	2.1 ± 0.2
IL-15	85.0 ± 3.4	68.6 ± 4.6
IL-16	119.7 ± 33.9	241.1 ± 67.9
IL17A	103.79 ± 6.5	44.74 ± 6.3
	= 0.001
IL17F	115.2 ± 8.3	44.7 ± 6.3
IL-18	118.3 ± 12.0	101.9 ± 24.3
IL21	184.3 ± 6.5	162.005 ± 16.1
IL22	163.5 ± 7.7	149.358 ± 18.7
IL23	481.4 ± 29.8	62.1517 ± 8.9
	< 0.000003
IL25	36.8 ± 1.9	32.4 ± 1.7
IL31	230.5 ± 14.2	195.055 ± 29.8
IL33	1050.4 ± 291.0	683.6 ± 158.2
CCL2	915.9 ± 46.9	145.6 ± 23.0
	= 0.0000001
CCL3	73.8 ± 7.1	35.7 ± 4.1
	< 0.05
CCL4	64.2 ± 8.9	47.5 ± 13.2
CCL5	8743.6 ± 2219.2	2589.5 ± 248.3
CCL7	337.4 ± 55.2	119.8 ± 6.3
CCL11	220.3 ± 25.0	113.5 ± 28.8
CCL27	4674.9 ± 643.3	854.6 ± 51.0
	< 0.05
CXCL1	342.9 ± 46.2	135.6 ± 40.6
CXCL9	2307.1 ± 338.7	2461.8 ± 301.6
CXCL10	1804.3 ± 264.6	732.2 ± 111.5
CXCL12	2575.6 ± 355.1	2582.4 ± 166.5
IFN-α2	59.8 ± 6.7	33.5 ± 8.0
INFγ	74.1 ± 4.1	77.3 ± 8.9
FGF basic	34 ± 24	56 ± 26
G-CSF	26.3 ± 2.9	19.7 ± 4.3
GM-CSF	45 ± 21	76 ± 34
HGF	1206.7 ± 164.1	931.7 ± 287.7
LIF	44.0 ± 7.9	29.2 ± 14.5
M-CSF	430.2 ± 41.7	37.3 ± 7.0
	= 0.002
MIF	401.1 ± 32.9	148.6 ± 38.9
	= 0.01
b-NGF	6.6 ± 0.4	6.7 ± 0.8
PDGF-bb	1256 ± 235	1462 ± 562
sCD40L	3592.9 ± 620.7	2756.0 ± 1007.3
SCF	230.5 ± 25.8	142.7 ± 18.9
SCGF-b	51782.6 ± 8900.2	46927.3 ± 7531.6
TNFα	39.8 ± 3.5	55.0 ± 5.3
TNF-β	10.4 ± 1.4	7.0 ± 1.5
TRAIL	252.3 ± 41.7	46.2 ± 10.0
VEGF	114.6 ± 12	74.4 ± 10.4